DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
McKesson (MCK) Announces Availability of FDA-Approved Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.
BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod
by Zacks Equity Research
BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.
Cooper Companies (COO) Q4 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) fourth-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid moderating expenses.
AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
by Zacks Equity Research
AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
Centene's (CNC) Ambetter Enhances Offerings With Broward Health
by Zacks Equity Research
Centene's (CNC) Health Insurance Marketplace brand Ambetter strengthens its provider network with Broward Health.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Centene (CNC), Mindoula to Address Mental Health Issues in Indiana
by Zacks Equity Research
Centene's (CNC) unit, MHS, collaborates with Mindoula to enhance mental health support for Hoosiers and attract more customers to opt for CNC's Medicaid plans.
DaVita HealthCare (DVA) Up 22.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.
Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both segments.
Top 5 Mid-Cap Stocks Likely to Turn Large-Cap in 2024
by Nalak Das
We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, XPO, AIZ, EME, DUOL.
Best Growth Stocks to Buy for December 7th
by Zacks Equity Research
EGHT, DVA and BBSI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 7, 2023.
3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.
Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact
by Zacks Equity Research
Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.
BD (BDX) Launches Advanced Vascular Access Management System
by Zacks Equity Research
BD's (BDX) SiteRite 9 Ultrasound System is likely to revolutionize vascular care by enhancing clinician efficiency and setting a new standard in first-attempt success.
West Pharmaceutical's (WST) New Launch to Expand Portfolio
by Zacks Equity Research
West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.
Best Growth Stocks to Buy for December 5th
by Zacks Equity Research
LMB, DVA and PK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 5, 2023.
The Zacks Analyst Blog Highlights Cboe Global Markets, Gartner, Intel, Royal Caribbean Cruises and DaVita
by Zacks Equity Research
Cboe Global Markets, Gartner, Intel, Royal Caribbean Cruises and DaVita are included in this Analyst Blog.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.
McKesson (MCK) Announces Availability of FDA-Cleared Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.
Top 5 High-Flying S&P 500 Stocks of November With More Upside
by Nalak Das
Five S&P 500 stocks with more potential are: IT, INTC, RCL, CBOE, DVA.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
Philips (PHG) Adds Smart Fit Coils to Boost Diagnostic Imaging
by Zacks Equity Research
Philips (PHG) launches three MR Smart Fit coils, namely TorsoCardiac 1.5T, 1.5T shoulder and Knee 3.0T, enhancing flexibility, reducing patient setup time and improving image quality resolution.